BioSpace News Archive

Carina Biotech Pty Ltd (Carina), a cell therapy immuno-oncology company, today announced that a poster presentation with preclinical data supporting the effectiveness of its LGR5-targeted CAR-T platform in ovarian cancer cell models will be presented at the 35th Annual Lorne Cancer Conference.

American Journal of Hematology recently published the phase 2 study result of BTK inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma patients.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted five employees nonqualified stock options to purchase 131,000 shares of its common stock with an exercise price of $7.10 per share, which is equal to the closing price of Kezar’s common stock on February 3, 2023, the grant date of the awards.

Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will participate at the following investor conferences.

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate at the following upcoming February 2023 virtual investor events.

T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has advanced to the Phase 2 accelerator in the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation’s (“Cohen Foundation”) LymeX Diagnostics Prize.

Ligand Pharmaceuticals Incorporated will report fourth quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, February 22, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter of 2022 after market close on Monday, February 27, 2023.

Collegium Pharmaceutical, Inc. announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.